| pubmed-article:21572789 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21572789 | lifeskim:mentions | umls-concept:C0004623 | lld:lifeskim |
| pubmed-article:21572789 | lifeskim:mentions | umls-concept:C0023283 | lld:lifeskim |
| pubmed-article:21572789 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:21572789 | lifeskim:mentions | umls-concept:C0205216 | lld:lifeskim |
| pubmed-article:21572789 | lifeskim:mentions | umls-concept:C0175668 | lld:lifeskim |
| pubmed-article:21572789 | lifeskim:mentions | umls-concept:C0231242 | lld:lifeskim |
| pubmed-article:21572789 | lifeskim:mentions | umls-concept:C0061366 | lld:lifeskim |
| pubmed-article:21572789 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:21572789 | pubmed:dateCreated | 2011-5-16 | lld:pubmed |
| pubmed-article:21572789 | pubmed:abstractText | Glucantime is regarded as the first-line treatment of cutaneous leishmaniasis (CL); however, failure to treatment is a problem in many cases. | lld:pubmed |
| pubmed-article:21572789 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21572789 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21572789 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21572789 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21572789 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21572789 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21572789 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21572789 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21572789 | pubmed:status | PubMed-not-MEDLINE | lld:pubmed |
| pubmed-article:21572789 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:21572789 | pubmed:issn | 1998-3611 | lld:pubmed |
| pubmed-article:21572789 | pubmed:author | pubmed-author:SadeghianGG | lld:pubmed |
| pubmed-article:21572789 | pubmed:author | pubmed-author:ZiaeiHH | lld:pubmed |
| pubmed-article:21572789 | pubmed:author | pubmed-author:BidabadiL... | lld:pubmed |
| pubmed-article:21572789 | pubmed:author | pubmed-author:BaghbaderaniA... | lld:pubmed |
| pubmed-article:21572789 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21572789 | pubmed:volume | 56 | lld:pubmed |
| pubmed-article:21572789 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21572789 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21572789 | pubmed:pagination | 37-9 | lld:pubmed |
| pubmed-article:21572789 | pubmed:dateRevised | 2011-7-28 | lld:pubmed |
| pubmed-article:21572789 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21572789 | pubmed:articleTitle | Decreased effect of glucantime in cutaneous leishmaniasis complicated with secondary bacterial infection. | lld:pubmed |
| pubmed-article:21572789 | pubmed:affiliation | Skin Disease and Leishmaniasis Research Center, Isfahan, Iran. | lld:pubmed |
| pubmed-article:21572789 | pubmed:publicationType | Journal Article | lld:pubmed |
